Blocking DHT does carry meaningful risks, though the severity varies widely from person to person, and the type of blocker matters. The drugs most commonly used to lower dihydrotestosterone, finasteride and dutasteride, have well-documented side effects ranging from sexual dysfunction to metabolic changes, with a smaller but concerning subset of users reporting symptoms that persist even after stopping the medication. Whether those risks are “bad” depends on why you’re blocking DHT, how aggressively you’re doing it, and your individual biology.
What DHT Does and Why People Block It
Dihydrotestosterone is a potent androgen that your body produces from testosterone using an enzyme called 5-alpha reductase. DHT is responsible for developing male external genitalia before birth, driving changes during puberty, and maintaining certain tissues throughout adulthood. It plays a particularly large role early in life: the ratio of free DHT to free testosterone is highest before puberty, reflecting how central DHT is to early male development.1PubMed. Free testosterone and free dihydrotestosterone throughout the life span of men In adults, DHT continues to influence the prostate, skin, hair follicles, and the nervous system.
People block DHT for two main reasons: to treat an enlarged prostate (benign prostatic hyperplasia) or to slow male pattern hair loss. Finasteride blocks one form of the 5-alpha reductase enzyme, while dutasteride blocks both forms, making it a more aggressive suppressor. In clinical trials, dutasteride reduced the risk of acute urinary retention and the need for prostate surgery, while also shrinking prostate volume and improving urinary flow.2PubMed Central. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia For hair loss, finasteride at the standard 1 mg dose reduces scalp DHT by roughly 64% and serum DHT by about 71%.3PubMed. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia That reduction is enough to slow or reverse hair miniaturization in many men, and studies confirm that the DHT-to-testosterone ratio drops sharply in the areas of the scalp most affected by balding.4PubMed. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration
The trouble is that DHT does more than shrink prostates and thin hair. When you suppress it systemically, you are also suppressing it in the brain, the liver, the eyes, and other tissues where it serves functions most people never think about.
Sexual Side Effects
Sexual dysfunction is the most widely discussed risk of DHT blockers, and the evidence for it is consistent. Clinical trials of 5-alpha reductase inhibitors report that roughly 5 to 9% of users develop new-onset erectile dysfunction while on the drug.5PubMed. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation Reduced sex drive and difficulty with orgasm also appear in trial data, both tied to the drop in circulating DHT. For most men who experience these effects, the problems resolve after stopping the medication.
But the picture gets murkier when you look beyond the controlled trial setting. One study of men who had developed persistent sexual problems after using finasteride for hair loss found strikingly high rates of dysfunction: 94% reported low libido, 92% reported erectile dysfunction, and 69% had trouble with orgasm. Their average number of sexual episodes per month dropped significantly.6PubMed. Persistent sexual side effects of finasteride for male pattern hair loss That study specifically recruited men who already had side effects, so those numbers do not reflect the experience of every finasteride user. But they do show that when sexual side effects do occur, they can be severe.
Post-Finasteride Syndrome
Some men report that sexual, neurological, and physical symptoms persist for months or years after they stop taking finasteride. This cluster of lingering problems has been labeled post-finasteride syndrome, and it includes low libido, erectile dysfunction, depression, anxiety, brain fog, and sometimes physical symptoms like muscle wasting or skin changes.7PubMed Central. Post-finasteride syndrome The definition typically requires that symptoms last at least three months after the drug is discontinued.
Follow-up research has found that these effects can be remarkably stubborn. In one study that reassessed men who had initially reported persistent sexual side effects, 96% still had them at follow-up, and 89% met clinical criteria for sexual dysfunction. Neither how long they had taken finasteride nor how long the side effects had been present predicted whether they would improve.8PubMed. Persistent sexual side effects of finasteride: could they be permanent? This remains one of the most unsettling findings in the literature on DHT blockers.
The medical establishment has been slow to embrace post-finasteride syndrome as a formal diagnosis. Critics point out that many studies of it rely on self-selected patients, lack control groups, and cannot rule out psychological factors like the nocebo effect. Supporters counter that the biological evidence is mounting, and that dismissing patients’ experiences as psychosomatic is premature. The condition is increasingly recognized as a real clinical problem, even if its exact prevalence remains uncertain.9PubMed Central. Post-finasteride syndrome: An emerging clinical problem
Neurological and Mood Effects
DHT is not just a sex hormone. It is also a precursor to neurosteroids, chemicals that help regulate brain signaling. When you block the enzyme that produces DHT, you simultaneously reduce the production of other steroid metabolites that influence mood, anxiety, and cognitive function. Some of these metabolites enhance the activity of GABA, the brain’s main calming neurotransmitter. Reducing them may leave some people more vulnerable to anxiety, depression, sleep problems, and emotional instability.10PubMed Central. 5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes
Researchers have measured these neurosteroid changes directly. In men who had taken finasteride for hair loss and were experiencing persistent side effects after stopping, cerebrospinal fluid showed decreased levels of several key neurosteroids, including metabolites of both progesterone and testosterone. At the same time, levels of precursor hormones like pregnenolone and testosterone itself were elevated, suggesting the enzymatic conversion pathway was still disrupted even after the drug was gone.11PubMed. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma These altered neuroactive steroid levels correlated with depressive symptoms.
Animal studies reinforce the concern. Rats given finasteride developed anxiety-like and depression-like behavior across multiple standard tests, along with impaired synaptic plasticity, a biological marker of how well brain cells communicate and adapt.12PubMed. Anxiety-, and depression-like behavior following short-term finasteride administration is associated with impaired synaptic plasticity and cognitive behavior in male rats These findings do not prove the same thing happens in every human user, but they provide a plausible biological mechanism for why some people feel mentally different on DHT blockers.
Metabolic Risks
One area that gets less attention than it should is what DHT blockers do to metabolism. The enzyme 5-alpha reductase does not only convert testosterone to DHT. It also processes other hormones, including cortisol. When you block it, you may be disrupting steroid metabolism in the liver and elsewhere in ways that promote fat accumulation and insulin resistance.
A review of the long-term health risks associated with finasteride and dutasteride raised concerns about nonalcoholic fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease, and potential kidney dysfunction.13PubMed Central. Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm These are not side effects that show up in a typical six-month hair loss trial, which is part of why they have been underappreciated.
Direct evidence backs up the concern. In a human study, dutasteride increased liver fat content in every participant who received it and boosted the liver’s glucose production rate, a sign of worsening insulin sensitivity. Finasteride showed similar trends, though they did not reach statistical significance in that small study, possibly because finasteride blocks only one of the two enzyme types.14The Journal of Clinical Endocrinology & Metabolism. Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man In rodent models, animals genetically lacking the type 1 form of 5-alpha reductase gained more weight on a high-fat diet, developed elevated insulin levels, accumulated more liver fat, and were more susceptible to liver fibrosis. Giving finasteride to obese rats produced similar results regardless of whether the animals still had functioning testes, suggesting the effect is driven by the enzyme blockade rather than by testosterone changes alone.15PubMed. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents
The practical implication: if you are already at risk for metabolic syndrome, fatty liver, or type 2 diabetes, long-term use of a DHT blocker, particularly dutasteride, deserves a conversation with your doctor about liver and metabolic monitoring.
Cardiovascular Safety
One area where the news is relatively reassuring is heart health. Early concerns that lowering DHT might increase cardiovascular risk have not been borne out by the available data. A systematic review of dutasteride studies found no statistically significant increase in the risk of heart failure, heart attack, or stroke compared to controls.16PubMed. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor – Dutasteride A separate large comparison of dutasteride and finasteride users also found no difference in risk of heart failure, heart attack, or stroke between the two drugs.17PubMed. The Cardiovascular Safety of Dutasteride This does not mean DHT blockers are perfectly safe for the cardiovascular system over decades, but the existing evidence does not point to a major heart-related risk.
Dry Eyes
A less well-known side effect involves the eyes. Androgens, including DHT, help maintain the lacrimal glands that produce tears and the meibomian glands that produce the oily layer of the tear film. Blocking DHT can disrupt this process. Animal studies have shown that finasteride induces significant tear deficiency and causes inflammatory cell infiltration of the lacrimal gland.18PubMed Central. Evaluation of a novel dry eye model induced by oral administration of finasteride If you are already prone to dry eyes or wear contact lenses, this is worth knowing about before starting a DHT blocker.
Prostate Cancer and Prevention
For years, there was excitement that DHT blockers might help prevent prostate cancer. Large trials did show that finasteride and dutasteride reduced the overall incidence of prostate cancer, but the cancers they prevented were overwhelmingly low-grade ones that might never have caused harm. They showed no reduction in advanced prostate cancer or death from prostate cancer.19PubMed. 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times? Given the current shift toward active surveillance for low-grade prostate cancer rather than aggressive treatment, the cancer-prevention angle for DHT blockers has become less compelling. You are unlikely to gain meaningful protection against dangerous prostate cancer by blocking DHT.
Bone Density and Lean Mass
Since DHT is a potent androgen, a reasonable worry is that blocking it might weaken bones or reduce muscle mass. In older men, both testosterone and DHT are comparably associated with lean body mass, with each hormone contributing similarly to maintaining muscle.20PubMed Central. Testosterone, Dihydrotestosterone, Bone Density, and Hip Fracture Risk among Older Men: The Cardiovascular Health Study However, the same study found no significant link between either hormone and hip or femoral neck bone mineral density after accounting for other factors. This suggests that while blocking DHT could theoretically affect body composition, the relationship between DHT and bones is more complex than a simple “lower DHT equals weaker bones” equation. Still, for men who are already losing muscle or at risk for osteoporosis, this is another factor to weigh.
What Genetic Models Tell Us
Some of the clearest evidence about what happens without DHT comes from people born with a genetic deficiency of the 5-alpha reductase type 2 enzyme. These individuals produce very little DHT from birth. Males with this condition are born with ambiguous genitalia, though internal reproductive structures develop normally. Their prostate remains extremely small throughout life, roughly a tenth of typical size, and they essentially never develop benign prostate enlargement or prostate cancer. At puberty they undergo some masculinization driven by testosterone, but they rarely develop significant body hair, male pattern baldness, or acne.21PubMed Central. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases
This natural experiment is important context. It shows that DHT is not essential for life or even for partial masculinization at puberty, but it is essential for full development of the external genitalia, prostate growth, and certain secondary sexual characteristics like body hair and scalp hair loss. The condition also provided the original rationale for developing DHT-blocking drugs: if people without DHT don’t get enlarged prostates, maybe pharmacologically mimicking that state would help men who do.
Topical Formulations as a Lower-Risk Option
One way to reduce the systemic risks of DHT blockade is to apply the drug directly to the scalp instead of swallowing it. A phase III trial comparing topical finasteride spray to oral finasteride found that the topical version produced plasma drug levels more than 100 times lower than the oral version. Topical finasteride still reduced serum DHT, but by about 35% rather than the roughly 56% drop seen with the oral form. The rate of side effects in the topical group was similar to placebo and lower than in the oral group.22PubMed Central. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
Topical finasteride is not zero-risk. Some of the drug still enters the bloodstream through the skin, and it does lower serum DHT to some degree. But for men whose primary concern is hair loss and who want to minimize their exposure, the topical route offers a compromise. It concentrates the drug where the hair follicles are, without flooding the rest of the body with as much enzyme blockade.
DHT Blockers in Women
Finasteride is primarily prescribed to men, but some dermatologists use it off-label for women with pattern hair loss. In postmenopausal women, small trials have shown modest benefit, with about two-thirds of patients showing some degree of improvement and no adverse reactions reported in the treated group.23PubMed. Finasteride treatment of female pattern hair loss The reason finasteride use in women remains limited and controversial has less to do with side effects in the women themselves and more to do with pregnancy risk. Finasteride can cause abnormal genital development in a male fetus. Because of this teratogenic potential, it is essentially off-limits for women who are or might become pregnant, and clinical research in premenopausal women has been restricted.24PubMed Central. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date Even handling crushed tablets is considered dangerous for pregnant women, since finasteride can be absorbed through the skin.
Natural DHT Blockers
Saw palmetto is the most widely marketed “natural” DHT blocker. It is available over the counter and has been used for decades as a prostate supplement. A systematic review of clinical studies found that saw palmetto-containing supplements did show positive effects on hair, including improved hair count, increased hair density, and stabilized hair loss in patients with androgenetic alopecia. The supplement was well tolerated with no serious adverse events.25PubMed Central. Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia
The catch is that saw palmetto’s DHT-lowering effect is weaker than what prescription drugs deliver, and the quality of supplements varies wildly since they are not regulated the same way as pharmaceuticals. For someone who wants mild DHT reduction with fewer systemic effects, saw palmetto may be reasonable, but expectations should be modest compared to finasteride or dutasteride. The theoretical risk profile is also milder precisely because the suppression is less aggressive, though this has not been rigorously tested in long-term studies.
How the Two Main Drugs Compare in Risk
Finasteride and dutasteride are often discussed interchangeably, but they are not the same drug and do not carry identical risk profiles. Finasteride blocks only the type 2 form of 5-alpha reductase, while dutasteride blocks both type 1 and type 2. This means dutasteride suppresses DHT more completely and in more tissues. The metabolic data bear this out: the study that found increased liver fat and insulin resistance showed clear effects with dutasteride, while finasteride’s effects on those same markers were more modest and did not reach statistical significance.14The Journal of Clinical Endocrinology & Metabolism. Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man Dutasteride also has a much longer half-life, meaning it stays in your system for weeks after you stop taking it, whereas finasteride clears within days.
For prostate conditions, dutasteride’s broader suppression may offer greater symptom relief. For hair loss, the marginal benefit of dutasteride over finasteride is debatable, and many clinicians prefer to start with finasteride because its narrower mechanism and shorter half-life make it easier to discontinue if problems arise. If you are considering DHT blockade primarily for cosmetic reasons, this risk-benefit calculus tilts toward the less aggressive option.
Who Should Be Most Cautious
The risks of DHT blockade are not evenly distributed. Certain groups face higher stakes:
- Young men: DHT plays a more prominent role in younger bodies. Starting a DHT blocker in your early twenties for hair loss means potentially decades of exposure, and the long-term metabolic and neurological consequences over that timeframe are not well-studied.
- People with mood disorders: Given the evidence linking DHT blockade to altered neurosteroid levels and depressive symptoms, anyone with a history of anxiety, depression, or suicidal ideation should discuss this risk explicitly with their prescriber before starting.
- Men with metabolic risk factors: If you already have fatty liver, prediabetes, or metabolic syndrome, adding a drug that may worsen insulin resistance and liver fat accumulation deserves careful thought.
- Women of childbearing age: The teratogenic risk to a male fetus makes finasteride functionally off-limits during pregnancy, and given the stakes, most clinicians avoid prescribing it to any woman who might conceive.
Conversely, older men taking finasteride or dutasteride for a genuinely bothersome enlarged prostate, where the alternative might be surgery, face a different calculus. The drug’s ability to shrink the prostate and reduce surgical risk may clearly outweigh its side effects for that population.
Monitoring and Practical Considerations
If you are on a DHT blocker or considering one, a few practical points are worth keeping in mind. First, DHT blockers lower your PSA reading by roughly half. Any doctor ordering a PSA test needs to know you are taking one of these drugs, or they may miss a concerning prostate reading. Second, if you develop sexual side effects, they typically appear within the first few months. Waiting to see if they resolve on their own is reasonable for mild symptoms, but persistent or worsening problems warrant stopping the drug and reassessing. Third, blood donation guidelines vary by country, but some agencies ask you to wait after stopping finasteride or dutasteride because of the potential harm to a pregnant recipient’s fetus.
If you do stop a DHT blocker and symptoms do not resolve within a few months, that is when the post-finasteride syndrome conversation becomes relevant. There is currently no proven treatment for post-finasteride syndrome, and the condition remains an active area of research. Endocrinologists and urologists familiar with it can offer supportive management, but honest clinicians will tell you that the evidence base for specific interventions is thin.